Prelude Therapeutics CFO departs; Bryant Lim named interim CFO

Prelude Therapeutics Inc

Laurent Chardonnet ceased as CFO on April 8, 2024; he will consult at $500/hr through Oct 4, 2024.
Bryant D. Lim, current Chief Legal Officer and Secretary, appointed interim CFO.
Chardonnet receives severance of $333,750 (9 months base salary) plus COBRA subsidy.
Consulting fee up to $50,000; Chardonnet's equity awards continue vesting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Bryant D. Lim

interim Chief Financial Officer

PRLD · Prelude Therapeutics Inc

Effective: 2024-04-08
Filed: April 10, 2024, 7:59 PM ET

Effective as of the Effective Date, the Board of Directors of the Company appointed Bryant D. Lim, the Company’s Chief Legal Officer and Corporate Secretary, as its interim Chief Financial Officer.

Departed

Laurent Chardonnet

Chief Financial Officer

PRLD · Prelude Therapeutics Inc

Effective: 2024-04-08
Successor: Bryant D. Lim
Filed: April 10, 2024, 7:59 PM ET

On April 8, 2024 (the “Effective Date”), Prelude Therapeutics Incorporated (the “Company”) and Laurent Chardonnet, the Company’s Chief Financial Officer, agreed that he will no longer serve as the Company’s Chief Financial Officer, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bryant D. Lim was appointed as interim Chief Financial Officer at Prelude Therapeutics Inc.

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

Effective as of the Effective Date, the Board of Directors of the Company appointed Bryant D. Lim, the Company’s Chief Legal Officer and Corporate Secretary, as its interim Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Laurent Chardonnet departed as Chief Financial Officer at Prelude Therapeutics Inc.

Action: agreed that he will no longer serve
Role: Chief Financial Officer

Exact text from the filing

On April 8, 2024 (the “Effective Date”), Prelude Therapeutics Incorporated (the “Company”) and Laurent Chardonnet, the Company’s Chief Financial Officer, agreed that he will no longer serve as the Company’s Chief Financial Officer, effective as of the Effective Date.

View on SEC.gov

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-043347

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.